One Last Run for the Bull Market?

Stan Harley |

As a market analyst, the problem I am always facing is one of incomplete information. Moreover, I am constantly plagued by a set of indicators and cyclical relationships that don’t always sing in unison. Some of my indicators will point to bullish, some will point to bearish. Divergences abound. It’s never easy, but I believe the best analysts recognize these problematic challenges for what they are and arrive at a decision based on the “weight of the evidence.”


In recent months my efforts have been primarily focused on calculating when the next major top is likely to occur. That still is my major focus, but in recent days I’ve come to the revisionist theory that this market has perhaps one more leg up before the bull market rocket fuel has been completely exhausted. In my monthly letter published on on this past Monday, I depicted my cyclical work highlighting a cycle averaging 318.4 months, which has denoted every high since the 1929 top. That cycle can vary, of course, but this cycle would suggest this market may continue higher into mid-March 2015.

Bullish Outlook Issued


On the S&P chart to the left I have depicted a high-to-high rhythm in play since the 11-Oct-2007 high averaging 64.4 months – roughly 315.2 trading days. Should the pattern continue, this cycle points to the March 18, 2015 time period for the next high. Although very late in the bull market, the pattern would suggest we have about 2½ months of additional rally. As such, I am advising a Bullish outlook for the broad market effective with today’s close. I’ll have a more expansive discussion on the cycles and risk I have under study in this weekend’s report.










Each month, Stan Harley publishes The Harley Market Letter, a newsletter that provides advanced technical analysis of stocks, bonds, and precious metals. This is the latest update to the Harley Market Letter for December. Want to learn more from acclaimed market analyst Stan Harley? Visit his site and subscribe to the full Harley Market Letter.  

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.